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2Abstract.
Lymphangioleiomyomatosis can be associated with reversible airflow obstruction and although no
guidelines around reversibility testing or inhaled therapy exist, many patients receive bronchodilators and
inhaled corticosteroids. To better identify those who may benefit, we examined bronchodilator reversibility
and inhaled therapy in a national cohort of 213 subjects. 20% of those tested had airway reversibility by
standard criteria. 55% of patients used 13 different combinations of bronchodilators and inhaled
corticosteroids. Increasing inhaler classes were associated with reversibility and more rapid FEV1 decline.
Reversibility testing should be performed in all patients and inhaled therapy should be formally studied.
3Introduction.
Lymphangioleiomyomatosis (LAM) is a rare disease of women categorised by lung cysts, pneumothorax,
lymphatic abnormalities and angiomyolipomas1. Loss of function of the tuberous sclerosis proteins, leads to
activation of the mTOR-signalling node; resulting in a clone of ‘LAM cells’ that infiltrate the lungs and
lymphatics causing tissue damage2. Treatment with mTOR inhibitors can slow disease progression3,4. LAM
cell associated airway narrowing results in airway obstruction which can be partially reversible and may be
associated with faster lung function decline5,6. Consequently, many women with LAM are treated with
bronchodilators and also inhaled corticosteroids (ICS).
Reversibility testing and inhaled therapy are not covered by current guidelines and how different
bronchodilator classes and ICS are used in women with LAM is unknown. This is of importance as
bronchodilators may improve quality of life and beta adrenoceptor agonists have been suggested as
potential adjuncts to mTOR inhibitors7, whereas ICS have not been studied. To identify who may benefit
from inhaled therapy and provide a baseline for interventional studies, we examined the prevalence and
clinical associations of reversible airway obstruction and the use of inhaled therapy in a national cohort of
women with LAM.
Methods.
Consecutive women with definite or probable LAM attending a national clinical centre were recruited
between 2011-188. At first visit, detailed clinical and drug history, lung function, computerised tomography
of the chest and abdomen were obtained. From 2015 onward, reversibility was routinely tested in response
to 2.5mg nebulized salbutamol. A positive response was defined as an increase in FEV1 of at least 12% and
200ml. Prospective loss of FEV1 was calculated from the slope of a regression line of sequential FEV1
measurements4. The East Midlands Research Ethics Committee approved the study and all subjects gave
written informed consent. Further details are given in the supplement.
4Results.
213 subjects were recruited, the mean age at onset of symptoms was 37 (standard deviation (SD) 12.9)
years and subjects were 50 (12.3) years at the time of the study. 95 subjects had had bronchodilator
reversibility testing. Subjects tested for reversibility were of similar age and lung function to those who
were not (see supplement). For those tested, the mean increase in FEV1 after salbutamol was 9.5% (10)
with 20% fitting pre-specified reversibility criteria.
In the 95 tested, reversibility was associated with airflow obstruction, younger age and lower gas transfer
(figure and table 1). Unsurprisingly, those with reversibility were more likely to be treated with
bronchodilators, but also ICS and rapamycin (table 1). 118 subjects (55%) were using at least one inhaled
drug. Indications for inhaled therapy were LAM in 68%, LAM with co-existent asthma or COPD in 18% and a
previous incorrect diagnosis of asthma or COPD in 13%.
Patients who used inhalers had longer disease duration (mean difference 3 years, 95% confidence interval
(C.I.) 0.5 to 5.6, p=0.019), lower FEV1 (mean difference -19% predicted, 95% C.I. -25 to -12, p=0.0001) and
DLCO (mean difference -12% predicted, 95% C.I. -17 to -6, p=0.0001). Thirteen combinations of inhaler
classes were used: these ranged from short acting beta agonists (SABA) alone in 20% of those treated; to
SABA, long acting beta agonist (LABA), long acting anti-muscarinic (LAMA) and ICS in 23%. 55% were using a
LAMA/LABA combination either alone or with other therapy (figure 1). We examined the relationship
between inhaler use and rate of FEV1 decline. As mTOR inhibitors affect FEV1 decline these patients were
excluded. 119 subjects had FEV1 measurements greater than 12 months apart (mean of 5.5 (3.2)
measurements over 47 (37) months). For all subjects, increasing inhaler class use was associated with
bronchodilator reversibility (r2 0.254, p<0.0001) and FEV1 decline (r2 0.052, p=0.012). Subjects not using
inhalers had a mean loss of FEV1 of 50 (110) ml/yr, whereas those treated with four inhaler classes lost 189
(480) ml/yr (mean difference 139 ml/yr, 95% C.I. -280 to -7, p=0.039). FEV1 decline was not different in
those treated with ICS and bronchodilators compared with bronchodilators alone (mean difference 15
ml/yr, 95% C.I. -146 to 116, p=0.81, table 2).
5Discussion.
Twenty percent of women with LAM fitted standard criteria for bronchodilator reversibility. Patients with
reversibility were younger, had lower DLCO values, and more were likely to be treated with inhalers and
rapamycin. Many had lower levels of reversibility that may also be clinically beneficial. Despite airflow
obstruction and dyspnoea many patients were not tested for reversibility (table 1). Over half of all patients
were prescribed inhalers, including ICS in almost one quarter. Inhaler use was associated with airflow
obstruction and reversibility and both bronchodilator and ICS use were associated with higher rates of FEV1
decline.
Our findings suggest that those with more advanced disease and rapid FEV1 decline are preferentially
treated with inhalers. Although the study was not designed to test efficacy, patients continued to take
bronchodilators suggesting they may improve symptoms, however disease progression did not appear
significantly improved by bronchodilators or ICS. Anecdotally, patients with airway obstruction and
reversibility are likely to benefit from bronchodilators and recent evidence suggests beta agonists may
affect disease activity in LAM7. However, which patient will benefit from which drug is unknown and
currently, while many are not being evaluated or treated, others may be over-treated and no consensus on
the optimal regimen exists. There have been no studies of ICS in LAM and their use may be based on an
initial misdiagnosis of asthma. Although a number of women will have asthma and LAM, these individuals
are likely to be identifiable from the history and investigations, whereas reversibility without other features
of asthma is likely to be due to LAM alone. As ICS are associated with an increased risk of pneumonia, we
suggest ICS be reserved for use in true co-existent asthma and clinical trials9.
Collectively, these observations highlight the need for prospective studies to determine the effect of
inhaled therapy on quality of life and disease progression in LAM. LAMA/LABA combinations are well
tolerated, more effective than single agents in COPD10, used frequently in LAM and seem appropriate
candidates to evaluate prospectively for LAM.
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7Table 1. Clinical associations with bronchodilator reversibility.
Bronchodilator reversibility p
(pres. v abs.)
(abs. v
not tested absent present
n 118 70 25
Age (years)* 50.7 (12.6) 50.7 (12.9) 44.9 (8.9) 0.04
Disease duration (years)* 9.2 (9.3) 9.0 (10.0) 7.2 (5.2) 0.41
Body mass index (m2/kg)* 26.5 (6.4) 25.8 (6.1) 25.5 (5.2) 0.86
WƌĞƐĞŶƟŶŐƐǇŵƉƚŽŵΏ
Dyspnoea 42 (50) 33 (23) 32 (8) 0.88
Pneumothorax 24 (28) 26 (18) 20 (5) 0.31
Other respiratory 11 (13) 11 (8) 16 (4) 0.42
Angiomyolipoma 14(17) 14 (10) 12 (3) 0.67
Other non-respiratory 3 (4) 3 (2) 4 (1) 0.70
Screened 1 (1) 6 (4) 4 (1) 0.51
None 5 (6) 9 (6) 4 (1) 0.10
Clinical phenotype†
Ever had pneumothorax 20 (24) 36 (25) 28 (7) 0.23
Angiomyolipoma present 52 (61) 53 (37) 48 (12) 0.48
Lymphatic complications 11 (13) 16 (11) 8 (2) 0.08
TSC present 20 (24) 10 (7) 16 (4) 0.20
Lung function*
FEV1 (% predicted) 74.1 (26) 74.4 (25) 63.8 (19) 0.06
TLCO (% predicted) 60.2 (19) 60.8 (16) 53.1 (13) 0.04
Treatment†
SABA 40 (48) 34 (24) 72 (18) 0.00005
LABA 31 (37) 47 (33) 80 (20) 0.000001
LAMA 23 (27) 39 (27) 76 (19) 0.00004
ICS 22 (26) 20 (14) 44 (11) 0.0003
Rapamycin 14 (17) 34 (24) 72 (18) 0.0005
Bronchodilator reversibility is defined by a >12% and >200ml increase in FEV1 following nebulised
salbutamol. *mean +/- standard deviation. †percentage of cohort (number of observations). SABA short
acting beta agonist. LABA long acting beta agonist. LAMA long acting muscarinic antagonist. ICS inhaled
corticosteroid. TSC tuberous sclerosis complex. p = comparison of present vs absent for bronchodilator
reversibility (pres. v abs.) by uncorrected, unpaired 2-tail t-test (*) or chi-square test (†).
8Table 2. Inhaler classes and lung function.
Inhaler
classes used
n FEV1
L (SD)
FEV1
% pred. (SD)
n reversibility
% (SD)
n ΔFEV1
ml/yr (SD)
0 95 2.31 (0.68) 84 (22.6) 30 2.0 (5.6) 60 -50 (110)
1 23 2.32 (0.80) 85 (27.4) 9 10.8 (6.1) 14 -20 (100)
2 30 1.74 (0.64) 64 (21.5) 22 11.7 (11.7) 14 -84 (140)
3 37 1.72 (0.66) 66 (26.1) 21 13.3 (6.5) 20 -125 (177)
4 28 1.29 (0.62) 49 (17.9) 13 16.3 (13.1) 12 -189 (480)
BD no ICS 62 1.94 (0.71) 71 (24.6) 40 12.4 (9.4) 37 -96 (160)
BD plus ICS 45 1.56 (0.81) 58 (25.9) 25 13.8 (11.0) 23 -120 (351)
Inhaler class: number of separate classes of inhaled therapy used from SABA, LABA, LAMA, ICS. BD no ICS:
any combination of SABA, LABA, LAMA. BD plus ICS: ICS and any combination of SABA, LABA, LAMA. %
pred: percentage of predicted FEV1 value. ΔFEV1 ml/yr: regression slope of FEV1 values in millilitres / year. L:
litres. Reversibility: percentage change in FEV1 following the administration of salbutamol. SD: standard
deviation.
9Figure legend
Figure 1. Reversibility and inhaler use in LAM. (a) Change in FEV1 in women with LAM in response to
salbutamol correlated with baseline FEV1. N=95, Pearson’s correlation r=-0.22 (95% confidence interval -
0.406 to -0.023) p=0.049. (b) Percentage women with LAM fitting criteria for bronchodilator reversibility
grouped according to baseline FEV1. White figures in columns represent the number tested in each group.
(c) Pie chart representing inhaler classes and combinations used to treat women with LAM. SABA short
acting beta agonist, LABA long acting beta agonist, LAMA long acting muscarinic antagonist, ICS inhaled
corticosteroid. Grey labels highlight bronchodilators only, white labels bronchodilators plus ICS.
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Supplementary methods.
Patient cohort and clinical assessment.
Women with LAM were recruited from the National Centre for LAM in Nottingham UK between 2011 and
2018. All subjects had definite or probable LAM defined by European Respiratory Society criteria1. The
study was approved by the East Midlands Research Ethics Committee (13/EM/0264) and all participants
gave written informed consent.
All measurements were taken as part of routine clinical care. At their first visit all subjects had a clinical
assessment, including a detailed history, screening for tuberous sclerosis complex (TSC), full lung function
and computerised tomography of the chest and abdomen to detect angiomyolipomas and lymphatic
involvement. Routine bronchodilator testing was introduced during the recruitment of the cohort in 2015,
from which time all subjects (95 of the cohort) also had bronchodilator reversibility testing. There was no
difference between the mean baseline FEV1 (unpaired 2-tailed t-test, p=0.72), DLCO (p=0.83) or age (p=0.17)
of the patients who had undergone bronchodilator reversibility testing and those who had not.
Age was that at baseline assessment, disease duration was defined as the time from first symptom that
could be attributed to LAM to the baseline assessment. Clinical phenotype was defined as the presence or
absence of a history of pneumothorax, angiomyolipoma, TSC or lymphatic manifestations at any point.
Drugs including all inhaled therapy and mTOR inhibitors were reported for the baseline visit only.
At each follow up visit, lung function was repeated. Follow up interval was determined by clinical need
based upon disease trajectory and ranged from 3 to 12 months between visits. As treatment with mTOR
inhibitors affects rate of loss of lung function we only used data on subjects prior to treatment with
rapamycin for LAM and did not include FEV1 values obtained once an mTOR inhibitor had been prescribed.
Not all subjects had data for bronchodilator reversibility testing or greater than one year of follow up
spirometry
Lung function.
Lung function measurements were made to American Thoracic Society standards2 in the same laboratory at
each visit. Loss of lung function was measured prospectively from the first assessment to the last follow up
at the time of writing. Rate of loss of lung function was calculated as the regression value for all FEV1
measurements providing this period was greater than 1 year to reduce variation in this measurement as
previously described3,4. Regression calculations were performed in Microsoft Excel.
Reversibility was tested in response to 2.5mg nebulized salbutamol, with a positive response defined as an
increase in FEV1 of at least 12% and 200ml2. In table 1, bronchodilator reversibility is presented as those
fitting the above criteria for bronchodilator reversibility (defined as present or absent). In table 2 and
elsewhere, bronchodilator reversibility is expressed as the mean percentage (+/- standard deviation)
change in FEV1 following administration of salbutamol.
Statistical analysis.
Differentiation between those with and without bronchodilator reversibility were performed by unpaired
two tailed t-test for continuous parametric variables (age, disease duration, body mass index, and lung
function) and chi square test for categorical variables (presenting symptom, phenotype and treatment).
Analysis of inhaler class and clinical and lung function variables was performed using two methods.
Comparison of patients who used inhalers, versus those who did not, with disease duration, FEV1 and DLCO,
was performed by uncorrected, unpaired two tailed t-test. Similarly, comparison of subjects not using
inhalers versus those treated with four inhaler types and FEV1 decline in those treated with ICS and
bronchodilators compared with bronchodilators alone were performed by unpaired two tailed t-tests.
Trends between increasing inhaler class use with bronchodilator response and rate of loss of FEV1 were
performed using linear regression.
A p value of 0.05 was accepted as significant and reported without corrections. Data were analysed using
Microsoft Excel and Graphpad Prism.
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